Modified-release Calcifediol Capsule clinical trials
Also written CTAP101.
A product of Calcifediol; its studies count on that page too.
How each study uses Modified-release Calcifediol Capsule is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Modified-release Calcifediol Capsule studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 5 Aug 1980 · CALDEROL · NDA 018312 (FDA, Drugs@FDA; as Calcifediol)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Related medicines
As reviewed, each with the page that says it.
- A dosage form of Calcifediol source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Modified-release Calcifediol Capsule.
- Oct 2027Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric ParticipantsPhase 2 · OPKO Health, Inc.
Studies
Open first, then newest update. How each study uses Modified-release Calcifediol Capsule is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric ParticipantsRecruitingPhase 2OPKO Health, Inc.NCT07494045Written as CTAP101
- Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary HyperparathyroidismTerminatedPhase 3OPKO Health, Inc.NCT05543928Written as CTAP101
- Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D InsufficiencyCompletedPhase 3OPKO IP Holdings II, Inc.NCT01651000Written as CTAP101 30 μg capsules
- Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D InsufficiencyCompletedPhase 3OPKO IP Holdings II, Inc.NCT01704079Written as CTAP101 30 μg capsules
- Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19CompletedPhase 2OPKO Health, Inc.NCT04551911Written as Rayaldee
- Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy SubjectsCompletedPhase 1OPKO Health, Inc.NCT03660800Written as CTAP101 Capsules
- Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic AcidCompletedPhase 1OPKO Health, Inc.NCT02274623Written as CTAP101 Capsules
- Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002CompletedPhase 3OPKO Health, Inc.NCT02282813Written as CTAP101 Capsules
- Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease SubjectsCompletedPhase 1OPKO IP Holdings II, Inc.NCT00888069Written as CTAP101 Capsules